Tag: solutions

CHANTILLY, Va., July 24, 2025 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company’s joint venture (JV) with Versar was awarded a $75 million single award delivery order contract by the United States Army Corps of Engineers (USACE) Middle East District for construction phase support services (CPSS). The contract includes a three-year base period of performance and a two-year option period. Parsons serves as the JV managing partner.

METTAWA, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Brunswick Corporation (NYSE: BC), today, released its second quarter 2025 financial results.  A complete and full-text financial results press release is available on the Company’s website at https://ir.brunswick.com.  The results will also be available on the SEC’s website with the Form 8-K filing of the release at http://goo.gl/wJQN1.

SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced a 21% increase in energy storage solutions (ESS) revenue in the first half of 2025 vs. 2024. Additionally, a purchase order was received from one of its largest ESS customers, for approximately $2 million, scheduled to be recognized as revenue by the end of 2025. The surge reflects Beam Global’s growing role as a trusted ESS supplier for mission-critical energy storage applications and the Company views repeat customers purchasing in increasing volumes as a strong validation of the reliability of its products.

SINGAPORE, July 24, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (NASDAQ: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today announced its financial results for the fiscal year ended March 31, 2025.

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.